1. In-ovo Newcastle disease virus vaccine strain TS09-C protects commercial chickens against Newcastle disease in the presence of maternally derived antibodies
- Author
-
Sanling Fan, Luo Qingping, Shang Yu, Huabin Shao, Wen Guoyuan, Zhang Tengfei, Luo Ling, Zhang Wenting, Yulun Wu, Zhang Rongrong, and Hongling Wang
- Subjects
Cellular immunity ,animal structures ,Newcastle Disease ,animal diseases ,medicine.medical_treatment ,Newcastle disease virus ,Passive immunity ,Biology ,Antibodies, Viral ,In ovo ,Newcastle disease ,Virus ,Injections ,03 medical and health sciences ,Immune system ,medicine ,Animals ,Poultry Diseases ,lcsh:SF1-1100 ,Ovum ,030304 developmental biology ,maternally derived antibody ,0303 health sciences ,Vaccination ,0402 animal and dairy science ,Viral Vaccines ,04 agricultural and veterinary sciences ,General Medicine ,Immunology, Health and Disease ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,040201 dairy & animal science ,Virology ,in-ovo vaccine ,embryonic structures ,biology.protein ,Animal Science and Zoology ,lcsh:Animal culture ,Antibody ,Chickens ,strain TS09-C - Abstract
Maternally derived antibodies (MDA) substantially interfere with active immunity in post-hatch vaccination, although they provide early protection against disease through passive immunity in young chickens. Previously, Newcastle disease virus (NDV) strain TS09-C was demonstrated to be safe and immunogenic as in-ovo vaccine in specific-pathogen-free chickens. Here, we evaluated the safety, protective efficacy, and duration of clinical protection of the TS09-C virus as an in-ovo vaccine for commercial chickens in the presence of Maternally derived antibodies against NDV. This vaccine was safe in commercial chickens and provided at least 80% protection against a virulent NDV challenge for 3 mo, despite inducing a low hemagglutinin-inhibition titer. For commercial chickens, the protective efficacy of the in-ovo vaccination was markedly higher than that of posthatch vaccination, and the cellular immune response might play an important role in the higher protective efficacy of the in-ovo vaccine. The overall results indicate that the maternally derived antibodies against NDV do not significantly interfere with the ability of the in-ovo vaccine strain TS09-C to induce protective cellular immunity.
- Published
- 2020
- Full Text
- View/download PDF